Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important
It's been a pretty good year for Juno Therapeutics (NASDAQ: JUNO) so far. The clinical-stage biotech's share price is up more than 50% year-to-date. Its financial position in the first quarter looked great thanks to its collaboration with Celgene (NASDAQ: CELG). And at the American Society of Clinical Oncology (ASCO) meeting in June, it reported positive data from an early stage study of lead candidate JCAR017 in treating aggressive B-cell non-Hodgkin lymphoma.
Juno provided an update on its second-quarter performance after the market closed on Thursday. Did things still look rosy? Here are the highlights.
Image source: Getty Images.
Source: Fool.com
